A

new federal effort is underway to keep biopharmaceutical manufacturing stateside — and scale up the production of complex biological drugs.

A new high-tech trade group, dubbed NIIMBL — the pithy shorthand for the National Institute for Innovation in Manufacturing Biopharmaceuticals — on Friday received $70 million from the Department of Commerce. On top of that, NIIMBL will be getting another $129 million from a public-private consortium of 150 companies, academic institutions, and nonprofits, as well as 25 states.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.